Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4786574
Max Phase: Preclinical
Molecular Formula: C76H119N21O18
Molecular Weight: 1614.92
Molecule Type: Unknown
Associated Items:
ID: ALA4786574
Max Phase: Preclinical
Molecular Formula: C76H119N21O18
Molecular Weight: 1614.92
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)O
Standard InChI: InChI=1S/C76H119N21O18/c1-8-42(6)61(71(111)94-56(74(114)115)36-41(4)5)95-68(108)54(38-45-22-26-47(99)27-23-45)93-70(110)58-19-14-34-97(58)73(113)51(17-12-32-84-76(81)82)88-63(103)48(16-11-31-83-75(79)80)87-69(109)57-18-13-33-96(57)72(112)50(15-9-10-30-77)89-67(107)55(39-59(78)100)90-62(102)43(7)85-65(105)53(37-44-20-24-46(98)25-21-44)92-66(106)52(35-40(2)3)91-64(104)49-28-29-60(101)86-49/h20-27,40-43,48-58,61,98-99H,8-19,28-39,77H2,1-7H3,(H2,78,100)(H,85,105)(H,86,101)(H,87,109)(H,88,103)(H,89,107)(H,90,102)(H,91,104)(H,92,106)(H,93,110)(H,94,111)(H,95,108)(H,114,115)(H4,79,80,83)(H4,81,82,84)/t42-,43-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,61-/m0/s1
Standard InChI Key: MGSQSJIDCGRMBG-JYDDPDNISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1614.92 | Molecular Weight (Monoisotopic): 1613.9042 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Chartier M,Desgagné M,Sousbie M,Côté J,Longpré JM,Marsault E,Sarret P. (2021) Design, Structural Optimization, and Characterization of the First Selective Macrocyclic Neurotensin Receptor Type 2 Non-opioid Analgesic., 64 (4.0): [PMID:33538583] [10.1021/acs.jmedchem.0c01726] |
Source(1):